Development of new preservation solution to maintain vascular endothelial Integlity.

A.研究血管活性物质对器官保存的影响。血管活性物质可减少中性粒细胞在再灌流肝组织中的渗入。在全肝血管阻断模型上，即使在肝脏完全热缺血2小时后，它们也能促进肝组织血流量的维持。此外，他们还试图显著恢复肝脏的能量代谢。例如，我们尝试了一种全新的Rho相关蛋白激酶Y 27632，以证明即使在肝脏缺血再灌注损伤中，Rho-Kinase也可以发挥关键作用。雄性SD大鼠采用70%部分肝缺血模型。动物分为两组，未处理组和热缺血90min前给予10 mg/kg Y-27632 P.O组，观察动物存活时间、动脉压、HART率、肝组织血流量、ALT、ET-1、透明质酸、髓过氧化物酶活性、Mac-1染色和病史。治疗组大鼠存活率、肝组织血流量、ALT、ET-1、HA、MPO明显改善，肝组织Mac-1阳性中性粒细胞浸润减少。c.采用犬自体肾移植模型，观察新型物质依达拉奉在HTK液中冷保存72小时后清除自由基的能力。实验动物随机分为两组，一组为治疗组，另一组为对照组。移植前系统输注依达拉奉，注入保存液中，移植后全身给药。治疗后尿量、NAG/Cr、FENA均有不同程度的改善，肾小管血肌酐、急性肾小管坏死、肾组织丙二醛水平明显降低。

A. The effect of vaso-reactive substances on the organ preservation were investigated. Vaso-active substances could reduce neutrophil infiltration into reperfused liver tissue. They also promoted the maintenance of hepatic tissue blood flow even after 2hr complete hepatic warm ischemia using total hepatic vascular occlusion model. Moreover, they attempted remarkable recovery of hepatic energy metabolism.B. For example, we tried a brand new Rho-associated protein kinase, Y 27632 to prove that Rho-kinase can play a key role even in the hepatic ischemia reperfusion injury. Male SD rats were engaged in a 70% partial hepatic ischemia model. Animals were divided into two groups, a no-treated group, a group treated with 10mg/kg Y-27632 p.o before 90 min warm ischemia, Survival, arterial pressure, hart rate, hepatic tissue blood flow, ALT, ET-1, Hyauronic acid, MPO activity, Mac-1 stain, and pathological history were investigated. The treatment ameliorated survival, hepatic tissue blood flow, ALT, ET-1, HA, and MPO, significantly, and also reduced the number of Mac-1 positive neutrophil infiltration into liver tissue.C. A brand new substance, edaravone, was tested for its ability as a radical scavenger using canine kidney auto transplantation model after 72hr cold preservation in HTK solution. Animal were randomly divided into two groups, treated one and untreated control. Edaravone was infused systematically before graft procurment, given into preservation solution, and administered systematically after grafting. The treatment unproved urine volume, NAG/Cr, FENa, and lessened Cr level, acute tubular necrosis, and MDA level in kidney draft.